Table 2.

Demographics and clinical characteristics of patients with inflammatory bowel disease who were included in the predictive analysis of disease course

Inflammatory bowel disease
	IBD escalation group [n = 67]	IBD non-escalation group [n = 212]
Males [%]	39 [58]	109 [51]
Smoking status [current: never: ex: missing]	16:34:16:1	36:98:77:1
Median FC [μg/g; range]	1631 [35–6001]	1186 [32–6001]
Median age [range], years	28 [18–67]	33 [18–77]
Edinburgh: Norway: Sweden: Spain	26:22:15:4	81:71:41:19
Disease subtype
Crohn’s disease	39	73
Ulcerative colitis	26	117
Inflammatory bowel disease unclassified [IBDU]	2	22
Ulcerative colitis
	Escalation group [n=26]	Non-escalation group [n=117]
Males [%]	19 [73]	67 [57]
Smoking status [current: never: ex: missing]	3:9:14:0	8:53:56:0
Median FC [range]	3778 [35–6001]	1367 [32–6001]
Median age [range], years	30 [18–60]	37 [18–77]
Edinburgh: Norway: Sweden: Spain	13:8:4:1	39:52:19:7
Paris extent for UC
E1 [proctitis]	0	38 [32%]
E2 [left sided]	7 [27%]	37 [32%]
E3 [pancolitis]	19 [73%]	42 [36%]
Crohn’s disease
	Escalation group [n = 39]	Non-escalation group [n = 73]
Males [%]	19 [49]	33 [45]
Smoking status [current: never: ex: missing]	13:5:20:1	26:18:28:1
Median FC [range]	1398.5 [47–6001]	825 [70–6001]
Median age [range], years	25 [18–66]	29 [18–73]
Edinburgh: Norway: Sweden: Spain	11:14:11:3	34:17:12:10
Montreal classification for CD
L1 [terminal ileum]	13 [33%]	25 [34%]
L2 [colonic]	9 [23%]	22 [30%]
L3 [ileocolon]	17 [44%]	25 [34%]
L4 [upper GI tract]	0	1 [1%]
Montreal behaviour for CD
B1, B1p [non-stricturing & non-penetrating, +perianal]	29, 0 [74%, 0%]	55, 6 [75%, 8%]
B2, B2p [stricturing, +perianal]	6, 0 [15%, 0%]	4, 0 [5%, 0%]
B3, B3p [penetrating, +perianal]	2, 2 [5%, 5%]	5, 1 [7%, 1%]
Not available	0	2 [3%]